FCCC LOGO Faculty Publications
Cohen SJ , Punt CJA , Iannotti N , Saidman BH , Sabbath KD , Gabrail NY , Picus J , Morse MA , Mitchell E , Miller MC , Doyle GV , Tissing H , Terstappen Lwmm , Meropol NJ
Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer
Annals of Oncology. 2009 Jul;20(7) :1223-1229
Back to previous list
Patients and methods: CTCs were enumerated with immunomagnetic separation from the blood of 430 patients with mCRC at baseline and on therapy. Patients were stratified into unfavorable and favorable prognostic groups based on CTC levels of >= 3 or < 3 CTCs/7.5 ml, respectively. Subgroups were analyzed by line of treatment, liver involvement, receipt of oxaliplatin, irinotecan, or bevacizumab, age, and Eastern Cooperative Oncology Group performance status (ECOG PS). Results: Seventy-one percent of deaths have occurred. Median follow-up for living patients is 25.8 months. For all patients, progression-free survival (PFS) and overall survival (OS) for unfavorable compared with favorable baseline CTCs is shorter (4.4 versus 7.8 m, P = 0.004 for PFS; 9.4 versus 20.6 m, P < 0.0001 for OS). In all patient subgroups, unfavorable baseline CTC was associated with inferior OS (P < 0.001). In patients receiving first- or second-line therapy (P = 0.003), irinotecan (P = 0.0001), having liver involvement (P = 0.002), >= 65 years (P = 0.0007), and ECOG PS of zero (P = 0.04), unfavorable baseline CTC was associated with inferior PFS. Conclusion: Baseline CTC count is an important prognostic factor within specific subgroups defined by treatment or patient characteristics.
Cohen, S. J. Punt, C. J. A. Iannotti, N. Saidman, B. H. Sabbath, K. D. Gabrail, N. Y. Picus, J. Morse, M. A. Mitchell, E. Miller, M. C. Doyle, G. V. Tissing, H. Terstappen, L. W. M. M. Meropol, N. J. 12 OXFORD UNIV PRESS; GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND 463OC